{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:55:37Z","timestamp":1777550137572,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"19","license":[{"start":{"date-parts":[[1984,10,1]],"date-time":"1984-10-01T00:00:00Z","timestamp":465436800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Wochenschr"],"published-print":{"date-parts":[[1984,10]]},"DOI":"10.1007\/bf01727445","type":"journal-article","created":{"date-parts":[[2005,6,13]],"date-time":"2005-06-13T05:25:57Z","timestamp":1118640357000},"page":"925-930","source":"Crossref","is-referenced-by-count":12,"title":["Transdermal clonidine application: Long-term results in essential hypertension"],"prefix":"10.1007","volume":"62","author":[{"given":"H.","family":"Groth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Kn\u00fcsel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Siegenthaler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF01727445_CR1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0160-5402(81)90069-3","volume":"6","author":"D Arndts","year":"1981","unstructured":"Arndts D, St\u00e4hle H, F\u00f6rster HJ (1981) Development of a RIA for clonidine and its comparison with reference methods. J Pharmacol Methods 6:295","journal-title":"J Pharmacol Methods"},{"key":"BF01727445_CR2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2133.1972.tb01907.x","volume":"86","author":"E Cronin","year":"1972","unstructured":"Cronin E (1972) Reactions to contact allergens given orally or systemically. Br J Dermatol 86:104","journal-title":"Br J Dermatol"},{"key":"BF01727445_CR3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cpt197619111","volume":"19","author":"CT Dollery","year":"1976","unstructured":"Dollery CT, Davies DS, Draffan GH, Dargie HJ, Dean CR, Reid JL, Clare RA, Murray S (1976) Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther 19:11","journal-title":"Clin Pharmacol Ther"},{"key":"BF01727445_CR4","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1600-0536.1978.tb03787.x","volume":"4","author":"L Ekenvall","year":"1978","unstructured":"Ekenvall L, Forsbeck M (1978) Contact eczema produced by a \u03b2-adrenergic blocking agent (alprenolol). Contact Dermatitis 4:190","journal-title":"Contact Dermatitis"},{"key":"BF01727445_CR5","first-page":"1079","volume":"307","author":"FT Frauenfelder","year":"1982","unstructured":"Frauenfelder FT (1982) Transdermal scopolamine precipitating narrow-angle glaucoma. N Engl J Med 307:1079","journal-title":"N Engl J Med"},{"key":"BF01727445_CR6","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/0002-9343(83)90812-4","volume":"74","author":"ED Freis","year":"1983","unstructured":"Freis ED, Materson BJ, Flamenbaum W (1983) Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. Am J Med 74:1029","journal-title":"Am J Med"},{"key":"BF01727445_CR7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0002-8703(79)90327-2","volume":"98","author":"W Frishman","year":"1979","unstructured":"Frishman W, Silverman R (1979) Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 3: Comparative clinical experience and new therapeutic applications. Am Heart J 98:119","journal-title":"Am Heart J"},{"key":"BF01727445_CR8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00005344-198000021-00007","volume":"2","author":"BN Garrett","year":"1980","unstructured":"Garrett BN, Kaplan NM (1980) Clonidine in the treatment of hypertension. J Cardiovasc Pharmacol 2:61","journal-title":"J Cardiovasc Pharmacol"},{"key":"BF01727445_CR9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF00609618","volume":"22","author":"AJ Georgopoulos","year":"1982","unstructured":"Georgopoulos AJ, Markis A, Georgiadis H (1982) Therapeutic efficacy of a new transdermal system containing nitroglycerin in patients with angina pectoris. Eur J Clin Pharmacol 22:481","journal-title":"Eur J Clin Pharmacol"},{"key":"BF01727445_CR10","first-page":"770","volume":"53","author":"A Graybiel","year":"1982","unstructured":"Graybiel A, Cramer DB, Wood CD (1982) Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration. Aviat Space Environ Med 53:770","journal-title":"Aviat Space Environ Med"},{"key":"BF01727445_CR11","first-page":"1841","volume":"113","author":"H Groth","year":"1983","unstructured":"Groth H, Vetter H, Kn\u00fcsel J, Boerlin HJ, Walger P, Baumgart P, Wehling M, Siegenthaler W, Vetter W (1983) Clonidin-TTS bei essentieller Hypertonie: Wirkung und Vertr\u00e4glichkeit. Schweiz Med Wochenschr 113:1841","journal-title":"Schweiz Med Wochenschr"},{"key":"BF01727445_CR12","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(83)90765-1","volume":"II","author":"H Groth","year":"1983","unstructured":"Groth H, Vetter H, Kn\u00fcsel J, Vetter W (1983) Allergic skin reactions to transdermal clonidine. Lancet II:850","journal-title":"Lancet"},{"key":"BF01727445_CR13","doi-asserted-by":"crossref","unstructured":"Guidelines for the treatment of mild hypertension (1983) Memorandum from a WHO\/ISH Meeting Lancet I:457","DOI":"10.1016\/S0140-6736(83)91451-4"},{"key":"BF01727445_CR14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1600-0536.1977.tb03708.x","volume":"3","author":"C Hindson","year":"1977","unstructured":"Hindson C (1977) Contact eczema from methyl salicylate reproduced by oral aspirin (acetyl salicyclic acid). Contact Dermatitis 3:348","journal-title":"Contact Dermatitis"},{"key":"BF01727445_CR15","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.1979.03300230028022","volume":"242","author":"Hypertension detection and follow-up program of a cooperative group","year":"1979","unstructured":"Hypertension detection and follow-up program of a cooperative group. Five-year findings of the hypertension detection and follow-up program. II. Mortality by race, sex and age (1979). J Am Med Assoc 242:2572","journal-title":"J Am Med Assoc"},{"key":"BF01727445_CR16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/000331978303400102","volume":"34","author":"A Karim","year":"1983","unstructured":"Karim A (1983) Transdermal absorption of nitroglycerin from microseal drug delivery (MDD) system. Angiology 34:11","journal-title":"Angiology"},{"key":"BF01727445_CR17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7326\/0003-4819-92-1-74","volume":"92","author":"J Lowenstein","year":"1980","unstructured":"Lowenstein J (1980) Clonidine. Ann Intern Med 92:74","journal-title":"Ann Intern Med"},{"key":"BF01727445_CR18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1600-0536.1975.tb05387.x","volume":"1","author":"H Maibach","year":"1975","unstructured":"Maibach H (1975) Acute laryngeal obstruction presumed secondary to thiomersal (merthiolate) delayed hypersensitivity. Contact Dermatitis 1:221","journal-title":"Contact Dermatitis"},{"key":"BF01727445_CR19","first-page":"851","volume":"II","author":"FG McMahon","year":"1983","unstructured":"McMahon FG, Weber MA (1983) Allergic skin reactions to transdermal clonidine. Lancet II:851","journal-title":"Lancet"},{"key":"BF01727445_CR20","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.1982.03330120023025","volume":"248","author":"Multiple Risk Factor Intervention Trial Research Group","year":"1982","unstructured":"Multiple Risk Factor Intervention Trial Research Group (1982) Multiple risk factor intervention trial. Risk factor changes and mortality results. J Am Med Assoc 248:1465","journal-title":"J Am Med Assoc"},{"key":"BF01727445_CR21","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1001\/jama.1982.03320470029019","volume":"247","author":"RK Osterholm","year":"1982","unstructured":"Osterholm RK, Camoriano JK (1982) Transdermal scopolamine psychosis. J Am Med Assoc 247:3081","journal-title":"J Am Med Assoc"},{"key":"BF01727445_CR22","first-page":"624","volume":"5","author":"S Popli","year":"1983","unstructured":"Popli S, Stroka G, Ing TS, Daugirdas JT, Norusis MJ, Hano JE, Gandhi VC (1983) Transdermal clonidine for hypertensive patients. Clin Ther 5:624","journal-title":"Clin Ther"},{"key":"BF01727445_CR23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/bmj.283.6296.875","volume":"283","author":"JE Shaw","year":"1981","unstructured":"Shaw JE, Urquhart J (1981) Transdermal drug administration \u2014 a nuisance becomes an opportunity. Br Med J 283:875","journal-title":"Br Med J"},{"key":"BF01727445_CR24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/000331978303400103","volume":"34","author":"RH Thompson","year":"1983","unstructured":"Thompson RH (1983) The clinical use of transdermal delivery devices with nitroglycerin. Angiology 34:23","journal-title":"Angiology"},{"key":"BF01727445_CR25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00003495-198223030-00003","volume":"23","author":"J Urquhart","year":"1982","unstructured":"Urquhart J (1982) Rate-controlled drug dosage. Drugs 23:207","journal-title":"Drugs"},{"key":"BF01727445_CR26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(84)90180-6","volume":"I","author":"MA Weber","year":"1984","unstructured":"Weber MA, Drayer JIM, Brewer DD, Lipson JI (1984) Transdermal continuous antihypertensive therapy. Lancet I:9","journal-title":"Lancet"},{"key":"BF01727445_CR27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/03602537808993784","volume":"8","author":"A Zaffaroni","year":"1978","unstructured":"Zaffaroni A (1978) Therapeutic systems: The key to rational drug therapy. Drug Metab Rev 8:191","journal-title":"Drug Metab Rev"}],"container-title":["Klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01727445.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01727445\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01727445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T18:00:10Z","timestamp":1586282410000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01727445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,10]]},"references-count":27,"journal-issue":{"issue":"19","published-print":{"date-parts":[[1984,10]]}},"alternative-id":["BF01727445"],"URL":"https:\/\/doi.org\/10.1007\/bf01727445","relation":{},"ISSN":["0023-2173","1432-1440"],"issn-type":[{"value":"0023-2173","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[1984,10]]}}}